Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Hereditary Angioedema
Clinical Trial
Last updated: 12/4/2025
Dawnzera
Froutine prevention of recurrent attacks of hereditary angioedema (HAE)
IONS
Ionis Pharmaceuticals, Inc.
